1.655
전일 마감가:
$1.64
열려 있는:
$1.62
하루 거래량:
124.12K
Relative Volume:
0.16
시가총액:
$87.70M
수익:
$139.77M
순이익/손실:
$-97.62M
주가수익비율:
-1.0475
EPS:
-1.58
순현금흐름:
$-61.71M
1주 성능:
+8.88%
1개월 성능:
+31.35%
6개월 성능:
-50.45%
1년 성능:
-88.83%
Macrogenics Inc Stock (MGNX) Company Profile
명칭
Macrogenics Inc
전화
301-251-5172
주소
9704 MEDICAL CENTER DRIVE, Rockville, MD
MGNX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
MGNX
Macrogenics Inc
|
1.655 | 87.70M | 139.77M | -97.62M | -61.71M | -1.58 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
501.81 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
568.09 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
629.64 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
259.07 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
248.21 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-11-07 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
2024-08-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
2024-07-31 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
2024-07-31 | 다운그레이드 | Guggenheim | Buy → Neutral |
2024-05-10 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2024-05-10 | 다운그레이드 | Stifel | Buy → Hold |
2024-05-10 | 다운그레이드 | TD Cowen | Buy → Hold |
2024-04-26 | 개시 | B. Riley Securities | Buy |
2024-04-09 | 업그레이드 | TD Cowen | Hold → Buy |
2024-03-04 | 재확인 | BTIG Research | Buy |
2024-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2023-12-20 | 업그레이드 | Citigroup | Neutral → Buy |
2023-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
2023-03-17 | 다운그레이드 | Guggenheim | Buy → Neutral |
2022-11-22 | 다운그레이드 | Cowen | Outperform → Market Perform |
2022-11-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2022-07-18 | 다운그레이드 | SMBC Nikko | Outperform → Neutral |
2022-07-11 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2022-05-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
2022-02-28 | 업그레이드 | Citigroup | Neutral → Buy |
2022-02-11 | 개시 | BMO Capital Markets | Outperform |
2022-02-04 | 개시 | SMBC Nikko | Outperform |
2021-11-17 | 재개 | Guggenheim | Buy |
2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
2021-10-15 | 재개 | BTIG Research | Buy |
2021-04-26 | 재개 | Credit Suisse | Outperform |
2021-03-12 | 업그레이드 | Barclays | Underweight → Overweight |
2020-12-22 | 재개 | H.C. Wainwright | Buy |
2020-08-03 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-06-01 | 업그레이드 | Guggenheim | Neutral → Buy |
2020-05-26 | 재확인 | H.C. Wainwright | Buy |
2020-03-04 | 개시 | Barclays | Underweight |
2019-12-19 | 개시 | Cantor Fitzgerald | Overweight |
2019-12-18 | 개시 | Cantor Fitzgerald | Overweight |
2019-11-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
2019-11-20 | 재개 | Guggenheim | Neutral |
2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
2019-04-12 | 개시 | Guggenheim | Neutral |
2019-02-07 | 업그레이드 | Citigroup | Sell → Buy |
2019-02-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
2019-02-06 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
2019-02-04 | 다운그레이드 | Citigroup | Neutral → Sell |
2018-12-10 | 다운그레이드 | Raymond James | Outperform → Underperform |
2018-09-10 | 재개 | BTIG Research | Buy |
2018-05-31 | 개시 | Evercore ISI | Outperform |
2018-03-05 | 개시 | H.C. Wainwright | Buy |
2017-03-31 | 개시 | Raymond James | Outperform |
모두보기
Macrogenics Inc 주식(MGNX)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
MGNXMacroGenics Provides Update on Corporate Progress and 2024 Financial Results - ADVFN
The MGNX Stock Puzzle: Unraveling Macrogenics Inc’s Fluctuating Performance - investchronicle.com
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results - ADVFN
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and Third Quarter 2015 Financial Results - ADVFN
Investor Expectations to Drive Momentum within LPL Financial, Comcast, MacroGenics, Wayfair, Masimo, and Big Lots — Discove... - ADVFN
MacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results - ADVFN
Comparing Ensysce Biosciences (NASDAQ:ENSC) & MacroGenics (NASDAQ:MGNX) - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.38 Average Price Target from Analysts - Defense World
MacroGenics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsMGNX - marketscreener.com
American Century Companies Inc. Buys Shares of 11,743 MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough - simplywall.st
Wellington Management Group LLP Acquires 16,717 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
ATTENTION MGNX SHAREHOLDERS: Investors who lost money on MacroGenics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Next Generation Immunotherapies Market Growth Projections - openPR.com
MGNX Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. (MGNX) Investors of Filing Deadline in Class Action Lawsuit - marketscreener.com
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lost Money on MacroGenics, Inc.(MGNX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
908 Devices Leads These 3 Penny Stocks To Consider - simplywall.st
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATTENTION MacroGenics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor SuitHagens Berman - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. LawsuitMGNX - ACCESS Newswire
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - ACCESS Newswire
MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Has $540,000 Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Macrogenics Inc (MGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Macrogenics Inc 주식 (MGNX) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
Eck Stephen L. | Chief Medical Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
34,319 |
Eck Stephen L. | Chief Medical Officer |
Feb 08 '25 |
Option Exercise |
0.00 |
11,168 |
0 |
20,966 |
SIEGEL JAY PHILIP | Director |
May 20 '24 |
Option Exercise |
0.00 |
4,500 |
0 |
4,500 |
자본화:
|
볼륨(24시간):